{"id":"W4283687131","doi":"10.1136/annrheumdis-2022-eular.1186","title":"POS1024 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 1","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"AbbVie","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Placebo; Adverse effect; Rheumatology; Clinical endpoint; Randomized controlled trial; Gastroenterology; Surgery; Arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003067855,0.0001956846,0.0005274416,0.00007739763,0.0005244511,0.000009935821,0.000491002,0.00006364939,0.0002977047],"category_scores_gemma":[0.001048796,0.0001577478,0.0002789537,0.0001774143,0.0004192403,0.00008859102,0.00029671,0.0001648981,0.000007533684],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000124154,"about_ca_system_score_gemma":0.0001195199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000430535,"about_ca_topic_score_gemma":0.000004416695,"domain_scores_codex":[0.9981993,0.0003721435,0.0007340495,0.0002843356,0.0001039362,0.0003062562],"domain_scores_gemma":[0.9973846,0.001391344,0.0005946053,0.0005357086,0.00008138449,0.00001232217],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01647722,0.004130438,0.0001037364,0.0002746733,0.002529122,0.000001551023,0.01282219,0.0009321873,0.004153506,0.004153091,0.006977111,0.9474452],"study_design_scores_gemma":[0.084198,0.006648051,0.6255929,0.004645622,0.002392951,0.00006417953,0.0437513,0.0006019935,0.0736629,0.07747674,0.07833698,0.002628332],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9312052,0.05940763,0.00003141707,0.001010224,0.0006409676,0.0007535982,0.006678672,0.00002893335,0.0002433777],"genre_scores_gemma":[0.9975843,0.00147366,0.00001549752,0.0001492463,0.000002618819,0.0000748042,0.0004186779,0.00001802303,0.0002631242],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9448168,"threshold_uncertainty_score":0.6432768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02236427850623391,"score_gpt":0.2571326608538491,"score_spread":0.2347683823476152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}